Tsis ntev los no, Novo Nordisk tau tshaj tawm nws daim ntawv tshaj tawm nyiaj txiag xyoo 2022. Cov ntaub ntawv qhia tau hais tias Novo Nordisk tag nrho cov muag khoom hauv 2022 yuav ncav cuag 176.954 billion Danish krone (US $ 24.994 billion, tus nqi pauv hloov pauv tau tshaj tawm hauv daim ntawv tshaj tawm txhua xyoo, tib yam hauv qab no), nce 26% xyoo rau xyoo, cov txiaj ntsig kev ua haujlwm yuav ncav cuag 74.809 billion Danish krone. (US $ 10.566 billion), nce 28% xyoo rau xyoo, thiab cov nyiaj tau los yuav yog 55.525 billion Danish krone (US $ 7.843 billion), nce 16% xyoo rau xyoo. Qhov kev ua tau zoo heev.

Novo Nordisk qhov kev ua tau zoo tuaj ntawm qhov twg? Cov lus teb yog GLP-1 analogue. Hauv Novo Nordisk cov raj xa dej, cov khoom tuaj yeem muab faib ua plaub hom: GLP-1 analogues, insulin thiab analogues, coagulation yam thiab lwm yam tshuaj hormones metabolic, nrog muag ntawm 83.371 billion Danish krone ($ 11.176 billion, tsis suav nrog koob poob), 52.952 billion Danish. krone ($ 7.479 billion), 11.706 billion Danish krone ($ 1.653 billion) thiab 7.138 billion Danish krone ($ 1.008 billion), feem. Ntawm GLP-1 analogues, kev muag khoom ntawm Liraglutide kev txhaj tshuaj hypoglycemic tau poob qis txhua xyoo, thaumSemaglutideyog qhov muag heev, nrog rau tag nrho cov muag khoom ntawm 10.882 billion nyiaj hauv 2022.